TW202216205A - 放射性藥劑及方法 - Google Patents

放射性藥劑及方法 Download PDF

Info

Publication number
TW202216205A
TW202216205A TW110125666A TW110125666A TW202216205A TW 202216205 A TW202216205 A TW 202216205A TW 110125666 A TW110125666 A TW 110125666A TW 110125666 A TW110125666 A TW 110125666A TW 202216205 A TW202216205 A TW 202216205A
Authority
TW
Taiwan
Prior art keywords
dotaga
euk
sub
iodo
compounds
Prior art date
Application number
TW110125666A
Other languages
English (en)
Chinese (zh)
Inventor
喬 麥肯
Original Assignee
加拿大商波因特生物製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 加拿大商波因特生物製藥股份有限公司 filed Critical 加拿大商波因特生物製藥股份有限公司
Publication of TW202216205A publication Critical patent/TW202216205A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW110125666A 2020-07-13 2021-07-13 放射性藥劑及方法 TW202216205A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063051335P 2020-07-13 2020-07-13
US63/051,335 2020-07-13
US202163143664P 2021-01-29 2021-01-29
US63/143,664 2021-01-29

Publications (1)

Publication Number Publication Date
TW202216205A true TW202216205A (zh) 2022-05-01

Family

ID=79171978

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110125666A TW202216205A (zh) 2020-07-13 2021-07-13 放射性藥劑及方法

Country Status (11)

Country Link
US (4) US11491246B2 (https=)
EP (1) EP4178628A4 (https=)
JP (1) JP2023539990A (https=)
KR (1) KR20240004205A (https=)
AU (1) AU2021309907A1 (https=)
BR (1) BR112023000763A2 (https=)
CA (1) CA3185565A1 (https=)
IL (1) IL299760A (https=)
MX (1) MX2023000623A (https=)
TW (1) TW202216205A (https=)
WO (1) WO2022013610A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4178628A4 (en) 2020-07-13 2025-04-02 Point Biopharma, Inc. RADIOPHARMACEUTICALS AND PROCEDURES
JP2025505307A (ja) * 2022-03-02 2025-02-21 ポイント・バイオファーマ・インコーポレイテッド 放射性医薬品及び方法
CN114404619A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
CN114404618A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其用途
WO2023215333A1 (en) * 2022-05-02 2023-11-09 Point Biopharma, Inc. Radiopharmaceutical and methods
CN115015441B (zh) * 2022-07-14 2023-08-18 原子高科股份有限公司 一种测定镥[177Lu]氧奥曲肽注射液中稳定剂含量的方法
CN119630434A (zh) * 2022-07-18 2025-03-14 库瑞姆美国有限责任公司 用于靶向分子成像的铜的放射性药物组合物
CA3263646A1 (en) * 2022-07-29 2024-07-18 Curium Us Llc [177lu] lutetium-psma l&t composition, kit, method of making, and method of using thereof
EP4568985A1 (en) * 2022-08-11 2025-06-18 Advancell Isotopes Pty Limited Radiopharmaceuticals
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途
KR20250073273A (ko) 2022-09-23 2025-05-27 누클리디움 아게 고순도 구리 방사성 의약 조성물 및 이의 진단 및 치료 용도
WO2024121722A1 (en) 2022-12-05 2024-06-13 Novartis Ag Method of treating prostate cancer
MX2025012292A (es) * 2023-04-14 2026-02-03 Fusion Pharmaceuticals Inc Terapia de combinación con inhibidores de la respuesta al daño de adn y radiofármacos dirigidos a psma
KR20260035965A (ko) 2023-07-11 2026-03-13 노파르티스 아게 전립선암의 치료 방법
CN121604981A (zh) 2023-07-21 2026-03-03 诺华公司 靶向psma的放射性配体治疗方案
WO2025029946A1 (en) * 2023-07-31 2025-02-06 Curium Us Llc [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
US12514939B2 (en) 2024-02-14 2026-01-06 Alpha-9 Oncology, Inc. Stable radiopharmaceutical compositions and uses thereof
WO2025235951A1 (en) * 2024-05-09 2025-11-13 Curium Us Llc Radiopharmaceutical compositions for actinium in targeted radionuclide therapy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005001415A2 (en) * 2003-05-23 2005-01-06 Epix Pharmaceuticals, Inc. Optically pure and enriched isomers of chelating ligands and contrast agents
JP5139678B2 (ja) 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
WO2016149188A1 (en) 2015-03-13 2016-09-22 The Johns Hopkins University 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN106660943B (zh) 2014-05-06 2020-03-17 约翰霍普金斯大学 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物
WO2018108287A1 (en) 2016-12-15 2018-06-21 The European Atomic Energy Community (Euratom), Represented By The European Commission Treatment of pmsa expressing cancers
CN111032632B (zh) 2017-05-30 2024-04-12 约翰霍普金斯大学 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596278B2 (en) * 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
IL281600B2 (en) 2018-09-21 2026-03-01 Endocyte Inc Cancer treatment methods
WO2020064693A1 (en) 2018-09-25 2020-04-02 Advanced Accelerator Applications (Italy) Srl Combination therapy
EA202191691A1 (ru) * 2019-01-30 2021-11-01 Технише Универзитет Мюнхен Радиоактивная метка, связывающая psma двумя способами, и терапевтическое средство
US11129912B1 (en) * 2020-07-13 2021-09-28 POINT Biopharma Inc. Radiopharmaceutical and methods
EP4178628A4 (en) 2020-07-13 2025-04-02 Point Biopharma, Inc. RADIOPHARMACEUTICALS AND PROCEDURES
CA3190855A1 (en) 2020-08-27 2022-03-03 Joe Mccann Radiopharmaceutical and methods
WO2022111800A1 (en) 2020-11-25 2022-06-02 Itm Solucin Gmbh Stable formulations for radionuclide complexes
CN118695876A (zh) 2021-11-29 2024-09-24 普安生物制药有限公司 放射性药物治疗方法和用途

Also Published As

Publication number Publication date
KR20240004205A (ko) 2024-01-11
US20220008564A1 (en) 2022-01-13
EP4178628A4 (en) 2025-04-02
BR112023000763A2 (pt) 2023-03-21
EP4178628A2 (en) 2023-05-17
US12558440B2 (en) 2026-02-24
IL299760A (en) 2023-03-01
US20230302163A1 (en) 2023-09-28
MX2023000623A (es) 2023-04-27
US20220016274A1 (en) 2022-01-20
JP2023539990A (ja) 2023-09-21
CA3185565A1 (en) 2022-01-20
WO2022013610A3 (en) 2022-03-17
US11491246B2 (en) 2022-11-08
AU2021309907A1 (en) 2023-03-02
US20240108765A1 (en) 2024-04-04
WO2022013610A2 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
TW202216205A (zh) 放射性藥劑及方法
US11129912B1 (en) Radiopharmaceutical and methods
TWI765451B (zh) 作為erk抑制劑的螺環類化合物及其應用
AU2004210191B2 (en) Improved radiometal complex compositions
JP7269668B2 (ja) インドール類似体及びその使用
TW202227143A (zh) 放射性藥物及方法
US20250127940A1 (en) Radiopharmaceutical and methods
CN116547007A (zh) 放射性药物和方法
CN101257929B (zh) 包含龙胆酸的稳定的123-i放射性药物
JPS58501726A (ja) 放射性診断剤製造用陽イオン化合物
JPH05505624A (ja) ラジオグラフィ造影剤として有用なヘキサデンテートリガンド類
CN118742332A (zh) 放射性药物和方法
KR20240155937A (ko) 방사성제약 및 방법
JP7299911B2 (ja) 肝臓の画像化用配位子としての新規なｄａｚａキレート剤
HK40088578A (zh) 放射性药物和方法
CN121752301A (zh) 用于治疗癌症的靶向psma的放射性药物